Aurex Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 181.91%
- Profit Growth 10.70%
- Ebitda -14.09%
- Net Worth -27.70%
- Total Assets -27.79%
About Aurex Laboratories
Aurex Laboratories Private Limited (ALPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 August 2015 (Nine years and six months 1 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Varun Aravapalli and Kanchana Arvapally serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24240TG2015PTC100187
-
Company No.
100187
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Aug 2015
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Aurex Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varun Aravapalli
|
Director | 24-Dec-2021 | Current |
Kanchana Arvapally
|
Director | 11-Aug-2015 | Current |
Financial Performance of Aurex Laboratories.
Aurex Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 181.91% increase. The company also saw a substantial improvement in profitability, with a 10.7% increase in profit. The company's net worth observed a substantial decline by a decrease of 27.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aurex Laboratories?
In 2023, Aurex Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ez Minds I.T Solutions Private LimitedVarun Aravapalli and Kanchana Arvapally are mutual person
-
Vsk Minerals And Metals Private LimitedVarun Aravapalli and Kanchana Arvapally are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aurex Laboratories?
Unlock and access historical data on people associated with Aurex Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aurex Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurex Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
